Gilder Gagnon Howe & Co. LLC lifted its holdings in shares of Athenex Inc (NASDAQ:ATNX) by 85.5% in the third quarter, HoldingsChannel.com reports. The firm owned 222,378 shares of the company’s stock after acquiring an additional 102,524 shares during the quarter. Gilder Gagnon Howe & Co. LLC’s holdings in Athenex were worth $3,456,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in ATNX. Barclays PLC grew its holdings in shares of Athenex by 426.5% during the 1st quarter. Barclays PLC now owns 5,913 shares of the company’s stock worth $100,000 after purchasing an additional 4,790 shares during the period. Legal & General Group Plc grew its holdings in shares of Athenex by 363.2% during the 2nd quarter. Legal & General Group Plc now owns 6,930 shares of the company’s stock worth $129,000 after purchasing an additional 5,434 shares during the period. Jane Street Group LLC purchased a new position in shares of Athenex during the 1st quarter worth $208,000. Metropolitan Life Insurance Co. NY purchased a new position in shares of Athenex during the 2nd quarter worth $266,000. Finally, A.R.T. Advisors LLC purchased a new position in shares of Athenex during the 1st quarter worth $289,000. Institutional investors and hedge funds own 19.87% of the company’s stock.
In related news, Director Song-Yi Zhang sold 102,734 shares of the stock in a transaction dated Wednesday, August 22nd. The stock was sold at an average price of $17.24, for a total transaction of $1,771,134.16. Following the transaction, the director now owns 4,000 shares of the company’s stock, valued at approximately $68,960. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Jinn Wu bought 5,000 shares of the firm’s stock in a transaction that occurred on Monday, August 20th. The shares were purchased at an average cost of $17.20 per share, for a total transaction of $86,000.00. Following the purchase, the director now owns 4,000 shares in the company, valued at approximately $68,800. The disclosure for this purchase can be found here. In the last three months, insiders have purchased 27,000 shares of company stock worth $405,120 and have sold 344,317 shares worth $5,859,972. 29.50% of the stock is currently owned by corporate insiders.
NASDAQ ATNX opened at $12.30 on Friday. The firm has a market cap of $770.93 million, a PE ratio of -5.30 and a beta of -1.67. Athenex Inc has a twelve month low of $11.49 and a twelve month high of $20.90.
Athenex (NASDAQ:ATNX) last posted its earnings results on Tuesday, August 14th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.48) by ($0.10). Athenex had a negative return on equity of 73.37% and a negative net margin of 122.29%. The firm had revenue of $11.57 million for the quarter. As a group, research analysts predict that Athenex Inc will post -1.77 earnings per share for the current year.
A number of research firms have recently weighed in on ATNX. BidaskClub upgraded Athenex from a “hold” rating to a “buy” rating in a report on Friday, July 6th. ValuEngine upgraded Athenex from a “hold” rating to a “buy” rating in a report on Friday, August 3rd. Zacks Investment Research cut Athenex from a “hold” rating to a “sell” rating in a report on Friday, August 17th. Finally, LADENBURG THALM/SH SH began coverage on Athenex in a report on Thursday, October 25th. They set a “buy” rating and a $27.00 price target for the company. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $23.60.
Athenex, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions. The company's Orascovery product candidates include Oraxol, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignances and gastric cancer; and Oratecan, an oral dosage form of irinotecan that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer.
Read More: Discount Rate
Want to see what other hedge funds are holding ATNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Athenex Inc (NASDAQ:ATNX).
Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.